MSD Animal Health Launches the IDAL® 3G Needle-free, Intradermal Swine Vaccination Device

The IDAL®Way” Features Newest Device with Broadest Vaccine Portfolio for Control of Major Diseases Affecting Swine.

MADISON, NJ, April 11, 2018 – MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced the launch of IDAL® 3G, the newest needle-free, intradermal delivery device in the IDAL® family of products for swine vaccination, and “The IDAL® Way,” an extended vaccine portfolio designed for intradermal use.
“The IDAL® Way” offers five intradermal swine vaccines for administration with the IDAL® 2G and the new IDAL® 3G, including PORCILIS® PCV ID, PORCILIS® M Hyo ID ONCE, PORCILIS® PRRS, PORCILIS® AD Begonia and PRIME PAC™ PRRS, an important step forward in controlling the major diseases affecting swine operations worldwide.
“Needle-free, intradermal application of vaccines is the most advanced method for vaccinating swine today, and The IDAL® Way is key for the future of swine production,” said Olivia Azlor, MBA, Director, Global Swine Marketing, MSD Animal Health. “We are proud to introduce the IDAL® 3G, which is designed to improve convenience and ease-of-use for producers, making vaccination safe and less stressful for pigs and people, while ensuring disease prevention with the broadest range of vaccines designed for intradermal administration.”
The third generation of the company’s needle-free IDAL® vaccine delivery system, IDAL® 3G has additional features that make the system easier to use. With a long-lasting Li-Ion battery and nearly twice the service interval of the IDAL® 2G, the IDAL® 3G also has a new balanced design, ergonomically shaped two-component surface for maximum grip, and intuitive handling with two-button control and graphical display.
The five intradermal swine vaccines for administration with IDAL® 2G and IDAL® 3G can protect swine from porcine reproductive and respiratory syndrome virus (PRRSv) and PRRSv-2, porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae (M Hyo) and Aujeszky’s disease virus infections (pseudorabies):

  • PORCILIS® PRRS: Modified live vaccine for immunization against PRRSv throughout the production system from as early as two week of age
  • PRIME PAC™ PRRS: Modified live vaccine for immunization of pigs as early as 2 weeks of age against PRRSv-2
  • PORCILIS® PCV ID: The first intradermal PCV vaccine for active immunization of pigs as early as 3 weeks of age to reduce PCV2 viremia, viral load in lung and lymphoid tissue and virus shedding in addition to loss of daily weight gain and mortality associated with a PCV2 infection
  • PORCILIS® M HYO ID ONCE: One-dose vaccine for immunization of piglets as early as 3 weeks of age to reduce lung lesions and decrease in daily weight gain during the finishing period following a Mycoplasma hyopneumoniae infection
  • PORCILIS® AD BEGONIA: Live, attenuated vaccine for the immunization of pigs against Aujeszky’s disease virus (Pseudorabies) infections

Producers and veterinarians can contact their MSD Animal Health representative for more information.

About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD.Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( 

Please see Prescribing Information for IDAL® at [] and PORCILIS® at [], [].